Compare Cronos Group Inc (CRON) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs MakeMyTrip Ltd — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while MakeMyTrip Ltd trades at $44.49 (market cap $4.09B). The key difference: MakeMyTrip Ltd is far larger — about 3.5× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and MakeMyTrip Ltd for 12 Days on average.
| CRON | MMYT | |
|---|---|---|
Market Cap | $1.18B | $4.09B |
Volume | 968,037 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $3.55 | $94.43 |
52-Week Low | $2.30 | $36.30 |
Typical Hold Time | 22 Days | 12 Days |
Enterprise Value | $387.62M | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
MMYT trades at $44.33, up 2.12% today, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, though net income margin remains thin at 3.23%. Analyst consensus is strongly bullish with a $77.00 price target, but institutional selling and a projected decline in 2026 cash flow pose concerns.
The stock presents a high-risk, high-reward opportunity. Strong analyst support and a potential Indian listing offer upside, but bearish technicals, earnings volatility, and rising debt-to-asset ratios in 2026 highlight significant risks. Investors should weigh the optimistic price targets against fundamental pressures and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
